Posts Tagged ‘VVUS’

Weekend Review of Unusual Options Trading (ACOR, CAAS, GME, HK, S, TEVA, VVUS)

Each Saturday we usually try to do a review of some unusual options trading at the end of the week.  With Friday being expiration date, that can always mask some of the larger trades.  We tracked unusual options trading in shares of Acorda Therapeutics, Inc. (NASDAQ: ACOR), China Automotive Systems Inc. (NASDAQ: CAAS), GameStop Corp. [...]

Unusual Options Patterns For What Lies Ahead (AA, BRCD, HAL, VVUS, UNG, SIRI)

We have scanned the options trades for highly unusual options trading patterns from Friday to see which will be carryover issues into next week.  Some may seem logical, while some may seem odd.  Friday’s highly unusual options trading that will carry over into next week was seen in Alcoa, Inc. (NYSE: AA), Brocade Communications Systems, [...]

Vivus Weight Loss Drug Effective Over Two Year Period

Vivus Inc. (NASDAQ: VVUS) is up 9.55% to $6.77 in pre-market trading following an announcement that the company’s experimental weight loss drug, Qnexa, helped overweight people lose an average of 11.4% of their body weight after two years in a clinical trial for the drug.  Vivus has already traded 460,503 shares, which is a significant [...]

VIVUS Options Signaling Huge Move (VVUS)

VIVUS, Inc. (NASDAQL VVUS) shares closed up strong on the week with a 21% gain despite a somewhat soft move Friday.  An analyst call from Wedbush and a downgrade the following day ahead of the FDA review next week.  The difference is that Wedbush believes the stock is a potential double.  The biggest action is [...]


VIVUS, Inc. (NASDAQ: VVUS) is trading higher this morning after the company announced that it has  submitted its Qnexa new drug application to the FDA for the treatment of obesity. This also includes weight loss and maintenance of weight loss in patients who are obese or overweight with co-morbidities such as hypertension, type 2 diabetes, [...]

VIVUS Mounting (VVUS)

VIVUS Inc. (NASDAQ: VVUS) is popping up hard this morning as the company may soon have a new erectile dysfunction drug on the market if the test results lead to an FDA approval.  It announced positive results in a phase 3 pivotal study evaluating the safety and efficacy of avanafil for the treatment of erectile [...]

VIVUS Up Again on Data (VVUS)

VIVUS Inc. (NASDAQ: VVUS) is trading up this morning on additional data on its Qnexa, the obesity investigational drug candidate with data being presented at the annual scientific meeting of The Obesity Society.  While the company’s top-line data from the phase III studies was out in September, the presentation included data from the EQUIP and [...]

Arena Not Good Enough, VIVUS Likes It (ARNA, VVUS)

Arena Pharmaceuticals, Inc. (NASDAQ: ARNA) came out with its news that it plans to submit its new drug ppplication for lorcaserin to the FDA in December after its one-year BLOSSOM trial met all primary efficacy and the safety endpoints. Arena also noted that patients achieved highly significant weight loss and was not associated with depression [...]

VIVUS Taking Out New Highs (VVUS)

VIVUS Inc. (NASDAQ: VVUS) is soaring on what is already exponential volume.  The company’s interim update showed that patients taking Qnexa reduced their weight by up to 14.7% on average in one trial, and the drug also showed improvement in blood pressure and diabetes symptoms and risk factors. Vivus’ second study showed an average weight [...]